Pipeline AIM Biologicals AEZS-150 AEZS-130 (Macimorelin) Macimorelin Dx
Overview
Latest News
Overview
Press Releases
Events
Analyst Coverage
Company Information
Stock Data
Financial Filings
Corporate Governance
Annual Reports
AGM Court Materials
Email Alerts
Stock Data
Company Overview
COSCIENS is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of significant unmet medical need. One of COSCIENS' lead products is macimorelin (Macrilen; Ghryvelin), the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). COSCIENS is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources currently used in cosmeceutical products (i.e., oat beta glucan and avenanthramides which are found in leading skincare product brands like Aveeno and Burt's Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.